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to EGFR inhibitors associated to chemotherapy (ChT), (2) to a VEGF inhibitor-associ-
ated to ChT or (3) submitted to ChT without monoclonal antibody: the patients with
RC cancer had an OS of 10,8mo. (CI 95% 6,81-14,79) in patients treated with EGFR
inhibitors versus 26,3mo. (CI 95% 19,78-32,82) in patients treated with VEGF inhibi-
tor versus 27,7mo. (CI 95% 23,05-32,35) in patients treated without monoclonal anti-
body, p¼ 0,051. In LC cancer, the OS was 54,9mo. (CI 95% 31,81-77,99) in patients
treated with EGFR inhibitors versus 23,9mo. (CI 95% 16,68-31,12) in those treated
with VEGF inhibitor versus 32,7mo. (CI 95% 19,71-45,69) in the others treated with-
out monoclonal antibody, p¼ 0,007.
Conclusion: The differences in RC versus LC survival were not statistically significative,
but the OS was slightly different between each other, as described in the literature. In
RC cancer the OS was superior in patients treated with VEGF inhibitors. On the other
hand, the OS in LC cancer was superior in patients treated with EGFR inhibitors.
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Introduction: Intra-abdominal neoplasms constitute themost important cause related to
splanchnic vein thrombotic (STV) events, followed by cirrhosis and inflammatory bowel
diseases. SVT is a heterogeneous illness that could affect the portal vein system, hepatic
vein system (Budd-Chiari Syndrome), splenic vein systemor uppermesenteric vein sys-
tem. It is an infrequent issue with an incidence of 0.5-0.7/100.000 patients/year,much less
frequent than deep vein thrombosis events. It can appear asymptomatically or with differ-
ent symptoms depending on its localization. Our aimwas to describe the incidence and
characteristics of splanchnic vein thrombosis events in a cohort of patients diagnosed with
Cholangiocarcinoma (CCA) in our center from January 2016 to June 2018.
Methods:Data from biliary tract cancer (BTC) patients treated in our center from
January 2016 till June 2018 were collected.We performed a retrospective search of SVT
in our cohort and analysed data about diagnosis, treatment and follow-up of this event.
Results: From January 2016 to June 2018 a total of 94 patients were diagnosed of BTC
in our center, including intrahepatic CCA (iCCA), perihilar CCA (pCCA), distal CCA
(dCCA), ampuloma and gallbladder cancer. 15 patients presented with an SVT event,
an incidence of nearly 15%. 80% of those patients were iCCA and 20%were pCCA.
67% of the patients hadmetastatic disease and 33% had locally advanced disease.
Anyone of those 15 patients had been treated with surgery. 75% of the cases were
asymptomatic and all of themwere diagnosed incidentally by CT scan at the same time
as the primary tumour. When symptomatic, ascites and pain were the most frequent
symptoms. 50% of the patients were treated with low weight heparin with a stabiliza-
tion of the thrombotic disease; two of them needed dose reduction due to chemother-
apy-related thrombocytopenia. However, no case of thrombotic disease progression
was observed among patients who did not receive anticoagulant therapy. When it refers
to the localization of the SVT, 80% of the events were in the portal vein. Less frequently
thrombosis affected suprahepatic or vena cava.
Conclusion: At the best of our knowledge, this is the first report about SVT in BTC
patients. In our cohort, 15% of the patients with CCAwere diagnosed with a splanchnic
thrombotic event. Most of themwere locally advanced or metastatic iCCA.
Thrombotic event was an incidental finding at diagnosis and behave asymptomatically
except in four patients who developed ascites or pain. Indication and benefit of anticoa-
gulation in those patients remains unclear. Treatment of this cancer complication
should be evaluated in prospective clinical trials.
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Introduction: A two-stage hepatectomy procedure (TSH)may be a curative approach
for patients with bilobar colorectal carcinoma liver metastases (CRLM). However, it is
not possible to complete this strategy as planned in about 20-40% of the cases. Aim: to
identify independent predictors for TSH strategy dropout.
Methods: Patients that met criteria for TSH concerning CRLM, were studied
(2000-2018; Tertiary hospital centre). Demographic and clinical evaluation was
performed.
Results: 196 patients, who were considered suitable for a TSH at baseline, ended up not
completing this strategy (32.7%; n¼ 64). Progression of the underlying oncologic dis-
ease was the main reason (70.3%). An adjusted multivariate classification approach was
used (dependent variable - complete or incomplete TSH; CRT algorithm): the variables
with the greatest discriminative power to explain strategy non-compliance were: N
from TNM staging (N0, N1a, N1c vs. N1b, N2a, b; p¼ 0.028), baseline Ca19.9 (cut
point 49.9; p¼ 0.028) and CEA (cut point 27.2; p¼ 0.021). For those patients who
completed the TSH procedure (n¼ 128), the 5-years overall survival was 35%.
Conclusion: Predictive factors for TSH non-compliance were N staging, CEA and
Ca19.9 levels. Two profiles of patients with a higher probability of having an
incomplete HDT strategy were identified: 1) N1b and N2 stagingþCa19.9 49.9; 2)
N0; N1a and N1c stagingþCEA 27.2. According to the authors’ knowledge, this is
one of the largest TSH series ever reported. Discriminating predictors of HDT dropout
may be important to identify patients whomight not benefit from this strategy at the
onset.
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Introduction: The aim of this work is to identify the clinical and prognostic character-
istics of metastatic colorectal cancer according to its right or left localization in patients
who have had RAS status study.
Methods: This was a prospective study of 40 patients followed for metastatic colorectal
cancer collected in the university department of medical oncology in Sfax during a 2-
year period (2017-2018) which looked at RAS status.
Results: There were 9 cases of right-sided colorectal cancers (RS) and 31 cases of left-
sided (LS). The mean age was 55.7 years in case of RS and 53 years for LS. The sex ratio
was 1 in the RS and 2 in the LS. Obesity was found in 50% of cases in each RS and LS.
The colloid contingent was found in 50% of RS and 26% of LS. Metastases were meta-
chronous in RS and synchronous in 91% of LS. The most commonmetastatic site was
peritoneum in RS (70%) and liver in LS (80%). Primary tumor surgery was performed
in both cases in 70%. Eighty percent of the LS had peri-nerve or vascular invasion ver-
sus 100% in the RS. The tumor was classified T4 and Nþ in 30% and 70% of the cases
respectively in each LS versus 50% and 100% in the RS respectively. The RAS was
mutated in 19% of LS and 25% of RS (p¼ 0.001). Themedian PFS was 13months and
9months for each of the LS and RS (p¼ 0.03). The median overall survival was 23
months and 18months for the LS and RS respectively (p¼ 0.02).
Conclusion:Our study showed that RAS gene was mutated in RSmore than LS.
Furthermore, it demonstrated that survival was significantly longer for patients with
primary tumors that originated on the left side of the colon.
P 250 The combined treatment of 150 kHz Tumor Treating Fields
(TTFields) and sorafenib shows In vitro and in vivo efficacy in
hepatocellular carcinoma
S Davidi1, K Gotlib2, E Zeevi1, R Shnaiderman1, T Voloshin1, M Giladi1, A Kinzel3,
U Weinberg1, E Kirson1, Y Palti1
1Novocure, Haifa, Israel, 2Novocure, Hiafa, Israel, 3Novocure GmbH, Munich, Germany
Introduction:Hepatocellular carcinoma (HCC) is the third cause of cancer-related
mortality and the primary cause of cancer death. Sorafenib, an oral multikinase inhibi-
tor is approved for patients with advanced HCC, yet its survival benefit is still limited.
Tumor Treating Fields (TTFields) therapy is an effective anti-neoplastic treatment
modality delivered via noninvasive application of low intensity, intermediate fre-
quency, alternating electric fields. TTFields are employed as a local treatment with the
intent to target dividing cells, leading tomitotic catastrophe and various forms of can-
cer cell death. The aim of this work is to explore the potential of the use of TTFields
alone and in combination with sorafenib as a treatment for HCC.
Methods:HepG2 andHuh-7D12 cells were treated with various TTFields frequencies
for 72 hours using the in-vitro system. Efficacy of the combined treatment of TTFields
and sorafenib was tested by applying TTFields at the optimal frequency together with
various drug concentrations. Cell counts, induction of apoptosis, cell cycle and clono-
genic potential were determined. N1S1 HCC cells were injected to the left lobe of the
liver of SD rats. After 1 week, TTFields (1.2 V/cm) and sorafenib were applied for 6 days
and tumor growth was followed usingMRI. Healthy rats were used to study the safety
of the use of TTFields (150 kHz) applied to the abdomen.
Results: The optimal TTFields frequency was 150 kHz for both cell lines. TTFields
application (1.0 - 1.7 V/cm, 72 hours) at 150 kHz led to 53-64% reduction in cell counts
and to an additional reduction of over 70% in the clonogenic potential. The combined
treatment of TTFields and Sorafenib led to a significant reduction in the number of cells
(2-way ANOVA, p< 0.001) as compared to each treatment alone. Tumor growth was
significantly reduced by the combined group compared to the control group (student
t-test, p< 0.01). Safety studies did not reveal any adverse event associated with
TTFields application to the rat abdomen.
Conclusion: These results demonstrated that TTFields can be a safe and effective treat-
ment against hepatocellular cancer and that the combination with sorafenibmay fur-
ther enhance treatment efficacy.
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